A number of other equities research analysts have also commented on the company. Vetr upgraded Allergan plc from a hold rating to a buy rating and set a $224.07 price target on the stock in a research report on Monday, January 23rd. Bank of America Corp reiterated a buy rating and issued a $280.00 price target on shares of Allergan plc in a research report on Friday, December 23rd. Piper Jaffray Companies set a $205.00 price target on Allergan plc and gave the company a hold rating in a research report on Wednesday, February 22nd. Leerink Swann upped their price target on Allergan plc to $280.00 and gave the company a buy rating in a research report on Thursday, February 9th. Finally, Goldman Sachs Group Inc lowered Allergan plc from a conviction-buy rating to a buy rating in a research report on Thursday, December 15th. Six research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus target price of $267.65.
Shares of Allergan plc (NYSE:AGN) traded up 0.64% during midday trading on Wednesday, reaching $239.36. The company had a trading volume of 803,114 shares. Allergan plc has a 12-month low of $184.50 and a 12-month high of $261.27. The stock’s 50 day moving average is $240.34 and its 200-day moving average is $221.55. The stock has a market capitalization of $80.24 billion, a PE ratio of 6.27 and a beta of 1.07. Allergan plc also was the recipient of some unusual options trading on Monday. Stock traders bought 1,437 call options on the company. This represents an increase of approximately 251% compared to the typical daily volume of 409 call options.
Allergan plc (NYSE:AGN) last released its quarterly earnings results on Wednesday, February 8th. The company reported $3.90 EPS for the quarter, beating analysts’ consensus estimates of $3.76 by $0.14. Allergan plc had a return on equity of 7.21% and a net margin of 100.04%. The firm had revenue of $3.86 billion for the quarter, compared to analyst estimates of $3.77 billion. During the same quarter in the previous year, the company posted $3.41 EPS. The business’s revenue was up 7.1% on a year-over-year basis. On average, equities research analysts predict that Allergan plc will post $16.04 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by sleekmoney and is owned by of sleekmoney. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at http://sleekmoney.com/allergan-plc-agn-given-a-279-00-price-target-at-royal-bank-of-canada/1739346.html.
In related news, Director Paul Bisaro sold 70,000 shares of the company’s stock in a transaction that occurred on Thursday, March 2nd. The stock was sold at an average price of $246.68, for a total transaction of $17,267,600.00. Following the transaction, the director now directly owns 274,226 shares of the company’s stock, valued at approximately $67,646,069.68. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 0.27% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of AGN. Wilbanks Smith & Thomas Asset Management LLC increased its position in Allergan plc by 0.7% in the third quarter. Wilbanks Smith & Thomas Asset Management LLC now owns 1,351 shares of the company’s stock worth $311,000 after buying an additional 9 shares during the period. Trust Co increased its position in Allergan plc by 0.7% in the fourth quarter. Trust Co now owns 1,214 shares of the company’s stock worth $255,000 after buying an additional 9 shares during the period. Apriem Advisors increased its position in Allergan plc by 1.2% in the third quarter. Apriem Advisors now owns 1,021 shares of the company’s stock worth $235,000 after buying an additional 12 shares during the period. High Point Bank & Trust Co. increased its position in Allergan plc by 3.6% in the third quarter. High Point Bank & Trust Co. now owns 717 shares of the company’s stock worth $165,000 after buying an additional 25 shares during the period. Finally, Mosaic Family Wealth LLC increased its position in Allergan plc by 2.3% in the third quarter. Mosaic Family Wealth LLC now owns 1,101 shares of the company’s stock worth $254,000 after buying an additional 25 shares during the period. 86.40% of the stock is currently owned by institutional investors and hedge funds.
Allergan plc Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/allergan-plc-agn-given-a-279-00-price-target-at-royal-bank-of-canada/1739346.html
Receive News & Ratings for Allergan plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan plc and related companies with MarketBeat.com's FREE daily email newsletter.